Company profile: AccuraGen
1.1 - Company Overview
Company description
- Provider of cancer early detection solutions: a liquid biopsy platform using unique biochemistry and machine learning to extract cancer signals in plasma for treatment guidance, minimal residue disease detection, and early screening; and CLAmp-seq technology to detect multiple cancer signals in blood and analyze them with machine learning for multi-cancer early detection tests.
Products and services
- CLAmp-seq Technology: Algorithm-driven, this assay detects multiple cancer signals in blood and analyzes data with a machine-learning algorithm to enable multi-cancer early detection tests
- Liquid Biopsy Platform: Plasma-based, this platform uses unique biochemistry and machine learning to extract various cancer signals in plasma for treatment guidance, minimal residue disease detection, and early screening
- Multi-Cancer Early Detection Tests: Blood-based, these products detect multiple cancer signals and analyze data with a machine-learning algorithm to support multi-cancer early screening
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to AccuraGen
Applied DNA Sciences
HQ: United States
Website
- Description: Provider of botanical DNA-based anti-counterfeiting, product authentication, and genetic testing solutions, offering Linea DNA for rapid, cell-free production of high-fidelity DNA for nucleic acid therapies; CertainT and SigNature DNA for supply chain source and authenticity verification; ADCL PCR-based virology testing; and TR8 pharmacogenomic testing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Applied DNA Sciences company profile →
Decipher Bio
HQ: United States
Website
- Description: Provider of genomic tests for urological cancers, including Decipher Prostate for risk scores to guide treatment decisions and Decipher Bladder for molecular subtyping to aid planning, and the Decipher GRID research platform of whole-transcriptome profiles. Continues to build its GRID database and partners with pharmaceutical companies to identify biomarkers of response to novel therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Decipher Bio company profile →
QurAlis
HQ: United States
Website
- Description: Provider of precision medicines for ALS and FTD, including therapeutic candidates QRL-201 to restore STMN2 expression and QRL-101 to reduce hyperexcitability-induced neurodegeneration by opening Kv7 channels, and platforms: QR43 to discover precision therapies for TDP-43-related diseases and FlexASO to develop antisense oligonucleotides that modulate RNA splicing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full QurAlis company profile →
Cepheid
HQ: United States
Website
- Description: Provider of accurate, easy-to-use molecular diagnostic systems and tests that automate complex procedures for institutions of any size. Offerings include the GeneXpert System and single-use Xpert cartridges for nucleic acid extraction, amplification, and detection, plus Xpert Xpress PCR tests for Strep A, SARS-CoV-2, CoV-2/Flu/RSV, and Flu A/B.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cepheid company profile →
Hexagon Bio
HQ: United States
Website
- Description: Provider of data-driven biotech solutions developing targeted small molecule therapeutics, including drug-target prediction via the TICker algorithm to identify microbial secondary metabolites that inhibit cancer-related proteins; DNA sequencing to build the world's largest database of microbial genomes and metabolites; compound production via the HEx platform using heterologous expression; and ADC payloads from natural products for oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hexagon Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for AccuraGen
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to AccuraGen
2.2 - Growth funds investing in similar companies to AccuraGen
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for AccuraGen
4.2 - Public trading comparable groups for AccuraGen
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →